AB Science presents the advances of AB8939 for acute myeloid leukemia

On December 17, 2024, AB Science revealed advances on AB8939, an innovative treatment for acute myeloid leukemia (AML). AB8939, a microtubule destabilizer, evades drug resistance and specifically targets cancer stem cells by inhibiting ALDH. It shows promising results in phase 1, without hematological toxicity.

The potential market for the treatment of refractory or relapsed AML is estimated at more than two billion euros per year. AB8939 has demonstrated efficacy in patients resistant to standard chemotherapies, including those carrying the MECOM gene, which is often associated with a poor prognosis.

Discussions are planned with the FDA and EMA to consider additional clinical studies. The intellectual property rights for AB8939 are protected until 2044.